As of Apr 17
| -0.54 / -3.03%|
The 6 analysts offering 12-month price forecasts for Theravance Inc have a median target of 16.50, with a high estimate of 47.00 and a low estimate of 7.00. The median estimate represents a -3.68% decrease from the last price of 17.13.
The current consensus among 7 polled investment analysts is to Hold stock in Theravance Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.